

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Nemolizumab for treating moderate to severe atopic dermatitis in people aged 12 and over or prurigo nodularis in adults ID6221

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> Galderma (nemolizumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> Allergy UK Changing Faces Eczema Outreach Support Let's Face It National Eczema Society Prurigo Nodularis International South Asian Health Foundation Specialised Healthcare Alliance <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> British Association of Dermatologists British Dermatological Nursing Group British Geriatrics Society British Skin Foundation British Society for Cutaneous Allergy Neonatal and Paediatric Pharmacists Group Primary Care Dermatology Society Royal College of General Practitioners Royal College of Nursing Royal College of Paediatrics and Child Health Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine St John's Institute of Dermatology UK Clinical Pharmacy Association 	<p><u>General</u></p> <ul style="list-style-type: none"> All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation Scottish Medicines Consortium Welsh Government Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> Abbvie (upadacitinib) Advanz Pharma (methotrexate) Aspen (azathioprine, mycophenolate mofetil) Cipla UK (methotrexate) Dexcel harma (ciclosporin) Eli Lilly (baricitinib) Hospira (methotrexate) LeoLaboratories (tralokinumab) Medac (methotrexate) Morningside Healthcare (methotrexate)

Provisional stakeholder list for the evaluation of nemolizumab for treating moderate to severe atopic dermatitis in people aged 12 and over or prurigo nodularis in adults ID6221
Issue date: May 2024

Consultees	Commentators (no right to submit or appeal)
<p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England 	<ul style="list-style-type: none"> • Mylan (azathioprine; ciclosporin, mycophenolate mofetil) • Nordic Pharma (methotrexate) • Nova (azathioprine; mycophenolate mofetil) • Novartis Pharmaceuticals (ciclosporin) • Orion Pharma (methotrexate) • Pfizer (abrocitinib; • Rosemont Pharmaceuticals (methotrexate) • Sandoz (methotrexate) • Santen UK (ciclosporin) • Strides Pharma (azathioprine, mycophenolate mofetil) • Tillomed Laboratories (azathioprine, mycophenolate mofetil) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Centre of Evidence-based Dermatology, University of Nottingham • Cochrane Skin Group • Dermatrust • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.